MDXG Stock — MiMedx Group Inc

MiMedx Group Inc (MDXG)

Updated October 16, 2026.

MDXG is a Stock. Its deepest 1-year drawdown was 61.2%.

MiMedx Group develops and distributes placental tissue allografts for wound care, surgical, and burn applications in healthcare. The company processes human placental tissues using its proprietary PURION technology to create products such as EPIFIX, EPICORD, and AMNIOFIX, which are sold through direct sales and distributors primarily in the United States. The company does not currently have an established distribution schedule.

MDXG performance

Returns are updating. MDXG's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 61.2%.

MDXG key facts

Asset type

Stock

Asset class

Equity

Inception date

08/22/2007

Distribution frequency

None

Last close

$4.43 (as of 2026-10-16)

Market cap

$646,488,949

Average volume

2728255.0

Beta

1.173

Payout ratio

0.0%

P/E ratio

110.75

Forward P/E

19.5313

EPS

$0.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MDXG risks and drawbacks

The deepest 1-year drawdown on record here is 61.2%.

Who may consider MDXG — and who may not

It is a weaker fit for investors who need monthly cash flow (MDXG does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MDXG

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions